Share

May 2019; 6 (3) Views & ReviewsOpen Access

Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy

Björn Ambrosius, Ralf Gold, Andrew Chan, Simon Faissner
First published April 4, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000551
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
911

Share

Article Information

vol. 6 no. 3 e551
DOI: 
https://doi.org/10.1212/NXI.0000000000000551
PubMed: 
31119186
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received November 3, 2018
  • Accepted in final form February 17, 2019
  • First Published April 4, 2019.
Copyright & Usage: 
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Björn Ambrosius, PhD,
    2. Ralf Gold, MD,
    3. Andrew Chan, MD and
    4. Simon Faissner, MD
  1. Björn Ambrosius, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Commercial, travel grant, 5000? Novartis for AAN 2016

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Celgene GmbH, associate Regional Medical Liaison, since September 2018

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. FORUM Anschubfinanzierung, Medizinische Faktult?t Ruhr Universit?t Bochum, F?rderkennzeichen: F859-15

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ralf Gold, MD,
    3. Scientific Advisory Boards:

    1. (1) TEVA Laquinimod DSMB

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker honoraria from Biogen, Genzyme, TEVA, Merckserono, BayerSchering,Celgene, Novartis

    Editorial Boards:

    1. SAGE Journal, Aktuelle Neurologie, Experimental Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Andrew Chan, MD and
    4. Scientific Advisory Boards:

    1. (1) Almirall (2) Actelion (3) Bayer (4) Biogen (5) Celgene (6) Genzyme (7) Merck (8) Novartis (8) Roche (9) Teva

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Almirall (2) Actelion (3) Bayer (4) Biogen (5) Celgene (6) Genzyme (7) Merck (8) Novartis (8) Roche (9) Teva; travel and speaker honoraria, all for University Research funds

    Editorial Boards:

    1. Clinical and Translational Neuroscience (Editorial board) Topic editor, Journal of International medical research

    Patents:

    1. (1) mTOR inhibition as mechanism to increase glucocorticosteroid efficacy

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from Biogen, Genzyme, UCB

    Research Support, Government Entities:

    1. (1) Schweizer Nationalfonds, Principle investigator, 2 years

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Swiss multiple sclerosis society, Co-PI, 2 years

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Simon Faissner, MD
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Speaker honoraria from Novartis, not related to the content of this manuscript.

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) V. W. Yong, M. Koch, S. Faissner. United States Patent Application No. 62/412,534 filed October 25, 2016, relating to, and entitled: Treatment for Progressive Multiple Sclerosis. (2) V. W. Yong, M. Koch, L. Metz, M. Mishra, S. Faissner. United States Patent Application No. 62/412,555 filed October 25, 2016, relating to, and entitled: Combination therapy with minocycline and hydroxychloroquine for the treatment of multiple sclerosis (MS).

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. (1) Medical Faculty of Ruhr-University Bochum, FoRUM (F898- 17), not related to this manuscript.

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (B.A., R.G., S.F.), St. Josef-Hospital, Ruhr-University Bochum, Gudrunstr, Bochum, Germany; and Department of Neurology (A.C.), University Hospital Bern, Bern University, Switzerland.
  1. Correspondence
    Dr. Ambrosius Bjoern.Ambrosius{at}ruhr-uni-bochum.de or Dr. Faissner Simon.Faissner{at}ruhr-uni-bochum.de
View Full Text

Article usage

Article usage: April 2019 to April 2022

AbstractFullPdfSource
Apr 20192147564Highwire
May 201976133101Highwire
Jun 20191510038Highwire
Jul 20193511525Highwire
Aug 2019119745Highwire
Sep 2019168629Highwire
Oct 2019710142Highwire
Nov 201938118Highwire
Dec 201958729Highwire
Jan 202057014Highwire
Feb 202049424Highwire
Mar 202028329Highwire
Apr 202038916Highwire
May 202037823Highwire
Jun 202053910Highwire
Jul 202076712Highwire
Aug 2020110420Highwire
Sep 202045517Highwire
Oct 202068126Highwire
Nov 202035623Highwire
Dec 202055418Highwire
Jan 202114924Highwire
Feb 20210338Highwire
Mar 202114024Highwire
Apr 202124811Highwire
May 202175318Highwire
Jun 202113514Highwire
Jul 202133822Highwire
Aug 202144010Highwire
Sep 202125020Highwire
Oct 202176827Highwire
Nov 202114727Highwire
Dec 202133511Highwire
Jan 202245021Highwire
Feb 2022145822Highwire
Mar 202247115Highwire
Apr 202246614Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Alert Me

Advertisement